BTG Launches LC Bead Lumi in the United States

April 1, 2016—BTG plc announced the United States launch of LC Bead Lumi, a radiopaque embolic bead for the embolization of hypervascular tumors and arteriovenous malformations (AVMs). LC Bead Lumi is a next-generation development of the company’s LC Bead. The company announced US Food and Drug Administration clearance for the device in December 2015.

According to the company, LC Bead Lumi’s visibility during and after embolization supports the optimization of patient treatment by enabling real-time visible confirmation of bead location during the procedure. This provides interventional radiologists more control and facilitates discovery of regions of under treatment, aiming to allow precise evaluation of the completeness of tumor treatment and enhanced end-point determination with long-lasting radiopacity to support follow-up management.

Raj Narayanan, MD, commented in BTG’s press release, “The launch of LC Bead Lumi has the potential to be a real game-changer in the field of embolization. Not only does it provide doctors and patients with reassurance that the tumor has been treated in its entirety, but it allows interventional radiologists like me to refine treatment as we go, with the subsequent prospect of improved outcomes for patients.” Dr. Narayanan is Associate Professor of Clinical Radiology at the University of Miami in Miami, Florida.